A5007280131- Bladder and Urothelial Cancer Treatments
- Testicular diseases and treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Sexual Differentiation and Disorders
- Multiple and Secondary Primary Cancers
- Urologic and reproductive health conditions
- Renal cell carcinoma treatment
- Sperm and Testicular Function
- Immunotherapy and Immune Responses
- Cancer survivorship and care
- Neuroblastoma Research and Treatments
- Ovarian cancer diagnosis and treatment
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Cutaneous Melanoma Detection and Management
- Palliative Care and End-of-Life Issues
- Sarcoma Diagnosis and Treatment
- Effects of Radiation Exposure
- Advanced Radiotherapy Techniques
- Immune cells in cancer
- Immune Cell Function and Interaction
- Lung Cancer Treatments and Mutations
- Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Metastasis and carcinoma case studies
Aarhus University Hospital
2004-2023
Rigshospitalet
2013-2023
Copenhagen University Hospital
2010-2023
Princess Margaret Cancer Centre
2000-2023
University of Copenhagen
1989-2018
Odense University Hospital
2000-2014
Hospital Universitario Virgen del Rocío
2012
Instituto de Biomedicina de Sevilla
2012
Aarhus University
2001-2011
Dana-Farber Cancer Institute
2010
PURPOSE: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium. PATIENTS AND METHODS: Patients stage IV TCC no prior systemic chemotherapy randomized to GC (gemcitabine 1,000 mg/m 2 days 1, 8, 15; 70 day 2) standard MVAC every 28 for a maximum six cycles. RESULTS: Four hundred five (GC, n = 203; MVAC, 202). The groups well-balanced respect prognostic...
Purpose To compare long-term survival in patients with locally advanced or metastatic transitional cell carcinoma (TCC) of the urothelium treated gemcitabine/cisplatin (GC) methotrexate/vinblastine/doxorubicin/cisplatin (MVAC). Patients and Methods Efficacy data from a large randomized phase III study GC versus MVAC were updated. Time-to-event analyses performed on observed distributions overall progression-free survival. Results A total 405 randomly assigned: 203 to arm 202 arm. At time...
Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional cell carcinoma of urothelial tract (TCCU). We conducted randomized phase III study VFL and best supportive care (BSC) versus BSC alone in the treatment patients with advanced TCCU who had experienced progression after first-line platinum-containing regimen. Patients Methods The was designed to compare overall survival (OS) between receiving + (performance status [PS] = 0: 320 mg/m 2 , every 3...
The aim of the study was to investigate association physician communication behaviours as perceived by patient with reported satisfaction, distress, cancer-related self-efficacy, and control over disease in cancer patients. Questionnaires measuring were completed prior after consultation 454 patients attending an oncology outpatient clinic. After consultation, also rated physicians' communicative completing a patient–physician relationship inventory (PPRI), physicians asked estimate...
Several management options are available to patients with stage I seminoma, including adjuvant radiotherapy, surveillance, and chemotherapy. We performed a pooled analysis of from the four largest surveillance studies better delineate prognostic factors associated disease progression.Individual patient data were obtained each center (Princess Margaret Hospital, Danish Testicular Cancer Study Group, Royal Marsden London Hospital) for 638 patients. Tumor characteristics (size, histologic...
The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial cancer. A phase I/II study suggested that three-drug included paclitaxel had greater antitumor activity and might improve survival.We conducted randomized III to compare paclitaxel/cisplatin/gemcitabine (PCG) GC carcinoma. Primary outcome was overall survival (OS). Secondary outcomes were progression-free (PFS), response rate, toxicity.From 2001 2004, 626...
Surgical resection provides long term survival in approximately 30% of patients with colorectal carcinoma (CRC) liver metastases. However, only a limited number CRC-metastases are amendable for surgery. We have tested the effect stereotactic body radiotherapy (SBRT) treatment inoperable CRC-metastases. Sixty-four total 141 (n = 44), lung 12), lymph nodes 3), suprarenal gland 1) or two organs 4) were treated SBRT central dose 15 Gy×3 within 5–8 days. Median follow-up was 4.3 years. After 2...
We have previously demonstrated a significant negative impact of intratumoral neutrophils in metastatic renal cell carcinoma. This study assessed localized clear carcinoma (RCC).The comprised 121 consecutive patients who had nephrectomy for RCC. Biomarkers (intratumoral CD8+, CD57+ immune cells, CD66b+ neutrophils, and carbonic anhydrase IX [CA IX]) were by immunohistochemistry, the relationship with clinical histopathologic features patient outcome was evaluated.The ranged from zero to 289...
PURPOSE The present study sought to identify pretreatment prognostic factors for overall survival (OS) in patients with metastatic transitional cell carcinoma of the urothelial tract (TCCU) who experienced treatment failure first-line, platinum-based regimen included phase III vinflunine trial. PATIENTS AND METHODS In total, 370 platinum-refractory TCCU were this analysis. Potential recorded prospectively. Univariate analysis was used clinical and laboratory that significantly impact...
To describe treatment results in a large cohort with stage I nonseminoma germ cell cancer (NSGCC) treated surveillance program.From January 1, 1984, to December 31, 2007, 1,226 patients NSGCC, including high-risk vascular invasion, were observed program.The relapse rate after orchiectomy alone was 30.6% at 5 years. Presence of invasion together embryonal carcinoma and rete testis the testicular primary identified group risk 50%. Without factors, 12%. Eighty percent relapses diagnosed within...
Carcinoma in situ the contralateral testis was diagnosed 27 of 500 patients (5.4%) with unilateral testicular germ cell cancer. Eight received intensive chemotherapy for spread their initial Follow up biopsy studies did not detect changes carcinoma any these patients, and none developed a tumour (observation time 12-88 months). Of remaining 19 situ, seven The estimated risk developing invasive growth 40% within three years 50% five years. None 473 without detected by screening cancer 12-96...
We aimed to create a prognostic model in metastatic melanoma based on independent factors 321 patients receiving interleukin-2 (IL-2)-based immunotherapy with median follow-up time for currently alive of 52 months (range 15–189 months). The were treated as part several phase II protocols and the majority received treatment intermediate dose subcutaneous IL-2 interferon-α. Neutrophil monocyte counts, lactate dehydrogenase (LDH), number sites, location metastases performance status all...
The purpose of this study was to evaluate the impact immunologic prognostic factors in combination with established clinical patients metastatic renal cell carcinoma (mRCC).A total 120 consecutive mRCC received interleukin-2 (IL-2) -based immunotherapy. Baseline tumor biopsies were available from 85 these patients. Potential analyzed by univariate and multivariate analyses.Multivariate analysis (N = 120) identified high lactate dehydrogenase, lymph node metastases, low hemoglobin, Karnofsky...
Abstract Purpose: Cisplatin-containing chemotherapy is the standard of care for patients with locally advanced and metastatic transitional cell carcinoma urothelium. The response rate ∼50% tumor-derived molecular prognostic markers are desirable improved estimation survival. Experimental Design: Affymetrix GeneChip expression profiling was carried out using tumor material from 30 patients. A set genes an highly correlated to survival time after identified. Two were selected validation by...
An elevated count of blood neutrophils and monocytes recently was shown independently to predict short survival in patients with stage IV melanoma undergoing interleukin-2-based immunotherapy. In this study, we aimed validate finding a large cohort patients.For retrospective prognostic the data from European Organisation for Research Treatment Cancer 18951 study were used. Patients randomly assigned between treatment dacarbazine, cisplatin, interferon alfa or without interleukin-2. Counts...